Hatchery-produced sandfish (Holothuria scabra) show altered genetic diversity in New Caledonia

Facing an alarming continuing decline of wild sea cucumber resources, management strategies were developed over the past three decades to sustainably promote development, maintenance, or regeneration of wild sea cucumber fisheries. In New Caledonia (South Pacific), dedicated management efforts via restocking and sea ranching programs were implemented to cope with the overharvesting of the sandfish Holothuria scabra and the recent loss of known populations. In order to investigate genetic implications of a major H. scabra restocking program, we assessed the genetic diversity and structure of wild stocks and hatchery-produced sandfish and compared the genetic outcomes of consecutive spawning and juvenile production events. For this, 1358 sandfish collected at four sites along the northwestern coasts of New Caledonia, as well as during five different restocking events in the Tiabet Bay, were genotyped using nine polymorphic microsatellite markers. We found that wild H. scabra populations from the northwestern coast of New Caledonia likely belonged to one panmictic population with high level of gene flow observed along the study scale. Further, this panmictic population displayed an effective size of breeders large enough to ensure the feasibility of appropriate breeding programs for restocking. In contrast, hatchery-produced samples did suffer from an important reduction in the effective population size: the effective population size were so small that genetic drift was detectable over one generation, with the presence of inbred individuals, as well as more related dyads than in wild populations. All these results suggest that dedicated efforts in hatcheries are further needed to maintain genetic diversity of hatchery-produced individuals in order to unbalance any negative impact during this artificial selection

Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting

Background: Incidence of perioperative in-stent thrombosis associated with myocardial infarction in patients undergoing major lung resection within 3 months of coronary stenting. Methods: Retrospective multi-institutional trial including all patients undergoing major lung resection (lobectomy or pneumonectomy) within 3 months of coronary stenting with non-drug-eluting stents between 1999 and 2004. Results: There were 32 patients (29 men and 3 women), with age ranging from 46 to 82 years. One, two or four coronary stents were deployed in 72%, 22% and 6% of the patients, respectively. The time intervals between stenting and lung surgery were ≪30 days, 30-60 days and 61-90 days in 22%, 53% and 25% of the patients, respectively. All patients had dual antiplatelet therapy after stenting. Perioperative medication consisted of heparin alone or heparin plus aspirin in 34% and 66% of the patients, respectively. Perioperative in-stent thrombosis with myocardial infarction occurred in three patients (9%) with fatal outcome in one (3%). Twenty patients underwent lung resection after 4 weeks of dual antiplatelet therapy as recommended by the ACC/AHA Guideline Update; however, two out of three perioperative in-stent thrombosis occurred in this group of patients. Conclusions: Major lung resection performed within 3 months of coronary stenting may be complicated by perioperative in-stent thrombosis despite 4 weeks of dual antiplatelet therapy after stenting as recommended by the ACC/AHA Guideline Updat

Development and validation of high-density SNP array in ducks

Development and validation of high-density SNP array in ducks. XIth European symposium on poultry genetics (ESPG

TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma

Metastasis is a multistep process and the main cause of mortality in lung cancer patients. We previously showed that EGFR mutations were associated with a copy number gain at a locus encompassing the TWIST1 gene on chromosome 7. TWIST1 is a highly conserved developmental gene involved in embryogenesis that may be reactivated in cancers promoting both malignant conversion and cancer progression through an epithelial to mesenchymal transition (EMT). The aim of this study was to investigate the possible implication of TWIST1 reactivation on the acquisition of a mesenchymal phenotype in EGFR mutated lung cancer. We studied a series of consecutive lung adenocarcinoma from Caucasian non-smokers for which surgical frozen samples were available (n = 33) and showed that TWIST1 expression was linked to EGFR mutations (P<0.001), to low CDH1 expression (P<0.05) and low disease free survival (P = 0.044). To validate that TWIST1 is a driver of EMT in EGFR mutated lung cancer, we used five human lung cancer cell lines and demonstrated that EMT and the associated cell mobility were dependent upon TWIST1 expression in cells with EGFR mutation. Moreover a decrease of EGFR pathway stimulation through EGF retrieval or an inhibition of TWIST1 expression by small RNA technology reversed the phenomenon. Collectively, our in vivo and in vitro findings support that TWIST1 collaborates with the EGF pathway in promoting EMT in EGFR mutated lung adenocarcinoma and that large series of EGFR mutated lung cancer patients are needed to further define the prognostic role of TWIST1 reactivation in this subgroup

Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma

<p>Abstract</p> <p>Background</p> <p>Lung cancer with EGFR mutation was shown to be a specific clinical entity. In order to better understand the biology behind this disease we used a genome wide characterization of loss of heterozygosity and amplification by Single Nucleotide Polymorphism (SNP) Array analysis to point out chromosome segments linked to <it>EGFR </it>mutations. To do so, we compared genetic profiles between <it>EGFR </it>mutated adenocarcinomas (ADC) and <it>KRAS </it>mutated ADC from 24 women with localized lung cancer.</p> <p>Results</p> <p>Patterns of alterations were different between <it>EGFR </it>and <it>KRAS </it>mutated tumors and specific chromosomes alterations were linked to the <it>EGFR </it>mutated group. Indeed chromosome regions 14q21.3 (p = 0.027), 7p21.3-p21.2 (p = 0.032), 7p21.3 (p = 0.042) and 7p21.2-7p15.3 (p = 0.043) were found significantly amplified in EGFR mutated tumors. Within those regions 3 genes are of special interest <it>ITGB8</it>, <it>HDAC9 </it>and <it>TWIST1</it>. Moreover, homozygous deletions at <it>CDKN2A </it>and LOH at <it>RB1 </it>were identified in <it>EGFR </it>mutated tumors. We therefore tested the existence of a link between EGFR mutation, CDKN2A homozygous deletion and cyclin amplification in a larger series of tumors. Indeed, in a series of non-small-cell lung carcinoma (n = 98) we showed that homozygous deletions at <it>CDKN2A </it>were linked to <it>EGFR </it>mutations and absence of smoking whereas cyclin amplifications (<it>CCNE1 </it>and <it>CCND1</it>) were associated to <it>TP53 </it>mutations and smoking habit.</p> <p>Conclusion</p> <p>All together, our results show that genome wide patterns of alteration differ between <it>EGFR </it>and <it>KRAS </it>mutated lung ADC, describe two models of oncogenic cooperation involving either <it>EGFR </it>mutation and <it>CDKN2A </it>deletion or cyclin amplification and <it>TP53 </it>inactivating mutations and identified new chromosome regions at 7p and 14q associated to EGFR mutations in lung cancer.</p

Impact du curage ganglionnaire médiastinal sur les métastasectomies pulmonaires (expérience de 247 cas sur 9 ans)

Objectif : L intérêt du curage ganglionnaire médiastinal, lors de la chirurgie des métastases du poumon, reste mal défini. Le but de notre étude est d évaluer l impact du curage ganglionnaire sur la survie du patient. Patients et Méthodes : Il s agit d une étude rétrospective unicentrique de 247 patients débutant de janvier 2003 à décembre 2012. Les patients ont bénéficié d une ou plusieurs métastasectomies pulmonaires et d un curage ganglionnaire indépendamment du cancer primitif. La probabilité de survie sans décès a été analysée. Résultats : L étude portait sur 156 hommes et 91 femmes avec un âge moyen de 60,1 ans. La résection complète était réalisée dans 88,5 % des cas. Les cancers primitifs étaient d origine colique (82), rectale (21), rénale (40), mélanome malin (25), sarcome (10), voile du palais (12), oesophage (5), hépatique (4), thyroïdienne (4), autres (23). Le curage des ganglions lymphatiques médiastinaux était positif dans 32 cas avec 22 stations N2 positives et 17 stations N1 positives. 23 patients ont récidivé avec des métastases controlatérales dont 4 patients avec des métastases ganglionnaires en station N2 parmi les 31 cas. On retrouvait un patient avec une deuxième récidive de métastase ganglionnaire. Le taux de récidive de métastases était de 11,5 %. Il n avait pas de résultats significatifs d une récidive ou de décès liée à l âge (p = 0,861 et p = 0,984). Les courbes concernant la probabilité de survie sans décès montrait une tendance à une survie inférieure à 50 % jusqu à 5 ans. Conclusion: Le curage ganglionnaire améliore la survie sans décès et sans récidive de métastases.BORDEAUX2-BU Santé (330632101) / SudocSudocFranceF